Opendata, web and dolomites

MAP-Detector

Development of a novel low dose, high resolution, high contrast X-ray detector for medical applications to improve patient diagnoses and reduce the risk of X-radiation induced cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAP-Detector project word cloud

Explore the words cloud of the MAP-Detector project. It provides you a very rough idea of what is the project "MAP-Detector" about.

detectors    enhanced    2017    13    technique    cdte    imaging    inspection       27    drafting    business    gt    compatible    dosage    clinical    trials    risk    cadmium    preparation    manufacturers    dose    incorporating    21    reduce    market    47    latter    retrofitted    seeking    conduct    exposes    plate    former    material       telluride    accounting    patented    4bn    leverage    mammography    accounted    materials    global    earlier    segment    culminate    map    medical    route    solutions    detection    industry    intend    innovative    detector    offers    requirement    share    rapid    diagnostic    cancer    patients    plan       grow    discrimination    exposure    50    ray    whilst    valuable    0bn    superior    1bn    2012    ibex    countries    significantly    certification    thoroughly    segments    keenly    plus    disruptive    2011    absorption    introduction    treatment    ct    showing    surpasses    fluoroscopy    initial    radiation   

Project "MAP-Detector" data sheet

The following table provides information about the project.

Coordinator
IBEX INNOVATIONS LTD 

Organization address
address: DISCOVERY 2 NETPARK
city: SEDGEFIELD
postcode: TS21 3FH
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.ibexinnovations.co.uk
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBEX INNOVATIONS LTD UK (SEDGEFIELD) coordinator 50˙000.00

Map

 Project objective

X-ray imaging is a valuable medical diagnostic technique, accounting for 47% of the medical imaging market in 2011. However, current X-ray detection technology exposes patients to increased risk of developing cancer with research in 13 developing countries showing that exposure to X-ray detection technology accounted for 0•6% to 1•8% of the cancer cases. X-ray detector manufacturers are thus keenly seeking technology that would reduce radiation exposure (dose) to patients whilst offering superior material discrimination for earlier detection and treatment of clinical cases. As IBEX, we have developed and patented an innovative X-ray detection technology incorporating our unique Multi Absorption Plate (MAP). Our technology significantly surpasses current solutions based on cadmium telluride (CdTe) as it offers potential dose reduction of >50% plus enhanced materials discrimination. MAP-Detector offers a disruptive X-ray detector that will leverage the MAP technology in both retrofitted and new build X-ray detectors for medical applications. The global medical diagnostic imaging market is expected to grow from €21.4bn in 2012 to €27.4bn by 2017, with X-ray and CT imaging equipment having a 50%/€13.1bn share in 2017. Within this segment, the X-ray imaging detector market is estimated at €2.0bn. Our technology will be compatible with the leading X-ray inspection systems creating significant market potential. Our initial target segments within the medical industry are fluoroscopy and mammography with dosage reduction being far more important for the former and materials discrimination an essential requirement for the latter. In Phase 1 we will thoroughly analyse the market to more clearly define our route to market and requirements for rapid market uptake. This will culminate in the drafting of a more detailed operational business plan. In Phase 2 we intend to conduct clinical trials and achieve certification for our technology in preparation for market introduction.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAP-DETECTOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAP-DETECTOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More